Patents Assigned to CUROGEN TECHNOLOGY CO., LTD.
  • Pharmaceutical composition for diagnosing, preventing or treating liver cancer using SSU72 protein or a polynucleotide encoding the same
    Patent number: 11918632
    Abstract: The present invention provides a method for preventing or treating liver cancer in a subject comprising administrating at least one selected from the group consisting of an Ssu72 peptide, a polynucleotide encoding the Ssu72 peptide and an expression vector containing the polynucleotide to the subject.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: March 5, 2024
    Assignees: CUROGEN TECHNOLOGY CO., LTD., RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
    Inventors: Chang Woo Lee, Jin Kwan Lee, Hyun Soo Kim, Jae-kyung Kim, Joon Sup Yoon
  • Pharmaceutical composition for treating non-alcoholic fatty liver, non-alcoholic steatohepatitis, or hepatic fibrosis using Ssu72 protein or a polynucleotide encoding the same
    Patent number: 11793862
    Abstract: The present invention provides a method for preventing or treating a liver disease selected from the group consisting of non-alcoholic fatty liver, non-alcoholic steatohepatitis and hepatic fibrosis comprising administrating at least one selected from the group consisting of an Ssu72 peptide, a polynucleotide encoding the Ssu72 peptide, and an expression vector comprising the polynucleotide.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: October 24, 2023
    Assignee: CUROGEN TECHNOLOGY CO., LTD.
    Inventors: Chang Woo Lee, Jin Kwan Lee, Hyun Soo Kim, Ji Hyun Choi, Se Eun Byeon, Hae In Lee, Hyeonju Jo
  • Method for inhibiting STAT3 activity comprising administering Ssu72
    Patent number: 11628206
    Abstract: The present disclosure relates to a method for inhibiting a STAT3 activity comprising administering SSu72 protein.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: April 18, 2023
    Assignee: CUROGEN TECHNOLOGY CO., LTD.
    Inventors: Mi-La Cho, Sung-Hwan Park, Seung-Ki Kwok, Jong-Young Choi, Seung-Hun Lee, Hyeon-Beom Seo, Young-Mee Moon, Jin-Sil Park, Min-Jung Park, Jin-Kwan Lee, Chang Woo Lee
  • METHOD FOR INHIBITING STAT3 ACTIVITY
    Publication number: 20210220447
    Abstract: The present disclosure relates to a method for inhibiting a STAT3 activity, and a method for treating inflammatory bowel disease (IBD).
    Type: Application
    Filed: January 21, 2021
    Publication date: July 22, 2021
    Applicant: CUROGEN TECHNOLOGY CO., LTD.
    Inventors: Mi-La CHO, Sung-Hwan Park, Seung-Ki Kwok, Jong-Young Choi, Seung-Hun Lee, Hyeon-Beom Seo, Young-Mee Moon, Jin-Sil Park, Min-Jung Park, Jin-Kwan Lee, Chang Woo Lee
  • Method of preventing rheumatoid arthritis comprising administering polynucleotide encoding SSU72
    Patent number: 10925933
    Abstract: The present disclosure relates to a method of preventing rheumatoid arthritis comprising administering a polynucleotide encoding Ssu72.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: February 23, 2021
    Assignee: CUROGEN TECHNOLOGY CO., LTD.
    Inventors: Mi-La Cho, Sung-Hwan Park, Seung-Ki Kwok, Jong-Young Choi, Seung-Hun Lee, Hyeon-Beom Seo, Young-Mee Moon, Jin-Sil Park, Min-Jung Park, Jin-Kwan Lee, Chang Woo Lee
  • PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOF
    Publication number: 20200396973
    Abstract: Provided are a psoriasis-induced transgenic animal model overexpressing the Pellino homolog 1 (Peli1) gene according to doxycycline administration, and a use thereof. The transgenic animal model of the present disclosure exhibited similarity to phenotypes shown in patients with psoriasis, due to overexpression of the Pellino homolog 1 (Peli1) gene according to doxycycline administration. It is anticipated that the transgenic animal model may be usefully used in clinical studies, such as screening for a candidate drug for the treatment of psoriasis. Additionally, it is anticipated that a peptide derived from the Peli1 FHA domain targeting the FHA binding motif that inhibits normal substrate binding between a substrate protein and the Peli1 protein may be usefully used in the development of new drugs for psoriasis-associated diseases. Moreover, by confirming an expression level of the Peli1 protein, it is anticipated to be usefully used in evaluating the severity of patients with psoriasis.
    Type: Application
    Filed: September 8, 2020
    Publication date: December 24, 2020
    Applicant: CUROGEN TECHNOLOGY CO., LTD.
    Inventors: Chang Woo LEE, Heoun Jeong GO, Su Hyeon KIM, Seo Yoon BAE